A national faculty development course for Pediatric Cardiac Anesthesiologists The CCAS CAFE program is a national initiative designed to advance the professional growth and engagement of pediatric … [Read More...]
WELCOME
CCAS is a society organized within the Society for Pediatric Anesthesia. The CCAS concept originated with cardiac anesthesia directors and other key leaders at major congenital heart disease programs, who believed there was a need for a new society because of rapid advancement of highly specialized knowledge in the field, and a great increase in the numbers of patients, including adults with congenital heart disease.
Join CCAS
Get Involved
Upcoming Events
Newsletters
Question of the Week
A 3-year-old child with tuberous sclerosis complex and a large cardiac rhabdomyoma develops increasing episodes of ventricular tachycardia. The cardiology team prescribes a medication specifically to reduce the size of the cardiac rhabdomyoma and improve the associated arrhythmia burden. Which of the following medications is MOST LIKELY to be prescribed, and what is its mechanism of action?
- A. Bevacizumab — inhibits vascular endothelial growth factor (VEGF) to reduce tumor angiogenesis
- B. Sirolimus — inhibits the mammalian target of rapamycin (mTOR), decreasing abnormal cellular proliferation
- C. Propranolol — nonselective beta-adrenergic receptor blocker, decreasing sympathetic tone
